Skip to content

13F-HR filed by Darwin Global Management, Ltd.

Darwin Global Management, Ltd. filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-16, with 12 holding rows worth $358,395,000.

Accession
0001420506-21-000329
Filed
2021-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 12 entries on the cover page, a total value of $358,395,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $358,395,000 with VALUE read as thousands by filing date, 13F file number 028-21006. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ACCELERON PHARMA INC00434H108COM938,490$120,070,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM952,847$86,642,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM260,876$57,299,000thousands by filing date
BRIDGEBIO PHARMA INC10806X102COM662,958$47,143,000thousands by filing date
SAREPTA THERAPEUTICS INC803607100COM114,900$19,589,000thousands by filing date
IMMUNOVANT INC45258J102COM199,269$9,204,000thousands by filing date
C4 THERAPEUTICS INC12529R107COM STK228,595$7,573,000thousands by filing date
GENERATION BIO CO37148K100COM197,191$5,590,000thousands by filing date
ARVINAS INC04335A105COM35,200$2,990,000thousands by filing date
INHIBRX INC45720L107COM36,534$1,205,000thousands by filing date
FULCRUM THERAPEUTICS INC359616109COMMON STOCK61,313$718,000thousands by filing date
STOKE THERAPEUTICS INC86150R107COM6,000$372,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-21-000329this filing2021-02-16acceptance time not in the bulk data set